Enveda

Enveda (also referred to as Enveda Biosciences) is a clinical-stage biotechnology company that applies machine learning, automation and metabolomics to characterize the chemistry produced by living organisms and translate it into small-molecule drug candidates. The company describes a proprietary "chemical sequencer" platform that reads complex natural mixtures, resolves molecular structures and characterizes activity, addressing the purification, structure-elucidation and characterization bottlenecks that historically made natural product drug discovery slow and expensive. Enveda has assembled a large collection of natural samples and built a database of chemical biodiversity intended to make this chemistry searchable at scale.

The company's lead candidate, ENV-294, is a first-in-class oral anti-inflammatory molecule discovered through its platform and represents a new chemical class with a distinct mechanism of action; in preclinical models it showed efficacy comparable to kinase inhibitors and steroids with a safety profile the company likens to biologics. Following Phase 1a studies in healthy volunteers, Enveda began a Phase 1b trial in moderate-to-severe atopic dermatitis. Its broader portfolio includes sixteen preclinical programs, more than a dozen development candidates and multiple IND-enabling studies, with planned expansion into asthma, inflammatory bowel disease and obesity.

Founding story

Enveda was founded in 2019 by Viswa Colluru, who holds a PhD in cellular and molecular biology and serves as CEO. Pieter Dorrestein of UCSD is listed as scientific co-founder.

Business model

Enveda develops proprietary small-molecule therapeutics discovered on its own platform and advances them through its internal pipeline into clinical trials, funded primarily by venture capital.

Traction

First Phase 1b trial initiated for ENV-294 in moderate-to-severe atopic dermatitis after Phase 1a studies in healthy volunteers showed safety and tolerability; sixteen preclinical programs, more than a dozen development candidates and multiple IND-enabling studies, with additional IND filings expected.

Latest developments

In September 2025 Enveda closed a $150 million Series D led by Premji Invest, appointed Mikael Dolsten to its board and began its first Phase 1b clinical trial of ENV-294. New capital is earmarked for advancing several clinical programs into Phase 1b and Phase 2 and supporting upcoming IND applications.